Paper Details
- Home
- Paper Details
Pharmacokinetic correlates of venlafaxine: associated adverse reactions.
Author: EndresKatharina, GründerGerhard, HaenEkkehard, HiemkeChristoph, PaulzenMichael, RiddersFlorian, SchoretsanitisGeorgios, VeselinovicTanja
Original Abstract of the Article :
To address the potential correlation between plasma concentrations of venlafaxine (VEN), its active metabolite O-desmethylvenlafaxine (ODVEN) and the active moiety, AM, (ODVEN + VEN) and adverse drug reactions (ADR) in a large naturalistic sample of in- and outpatients. We compared plasma concentrat...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1007/s00406-019-01005-0
データ提供:米国国立医学図書館(NLM)
Venlafaxine: Unveiling the Complexities of Adverse Drug Reactions
The [use of venlafaxine] is a common therapeutic strategy, but understanding its [pharmacokinetic correlates and associated adverse reactions] is essential for patient safety and optimal treatment outcomes. This research investigates the potential link between venlafaxine plasma concentrations, its active metabolite, and adverse drug reactions (ADRs) in a large naturalistic sample of patients.
A Complex Landscape: Exploring the Relationship Between Venlafaxine and ADRs
The study's findings do not demonstrate a direct link between venlafaxine metabolism measures and ADRs. This suggests that other factors, potentially beyond pharmacokinetics, may contribute to the development of ADRs in patients receiving venlafaxine. Further research is needed to unveil the intricate interplay between venlafaxine, its metabolism, and the occurrence of ADRs.
Navigating the Desert of ADRs: Understanding Venlafaxine's Complexities
The study's findings highlight the need for a more comprehensive understanding of the factors contributing to ADRs in patients receiving venlafaxine. While pharmacokinetics might play a role, other factors like individual patient characteristics and genetic variations might also influence the likelihood of ADRs. This understanding is essential for optimizing venlafaxine treatment and minimizing potential adverse effects.
Dr.Camel's Conclusion
The desert of pharmacokinetic research can be vast and complex. This study underscores the need for a deeper understanding of the factors contributing to ADRs in patients receiving venlafaxine. The intricate interplay between pharmacokinetics, individual patient characteristics, and genetic variations might be the key to unlocking the secrets of ADRs, ultimately leading to improved patient safety and treatment outcomes.
Date :
- Date Completed 2020-02-10
- Date Revised 2020-02-25
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.